A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs CX 8998 (Primary)
- Indications Arrhythmias; Essential tremor
- Focus Proof of concept; Therapeutic Use
- Acronyms T-CALM Sudy
- Sponsors Cavion
- 05 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 05 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
- 20 Sep 2017 According to a Cavion media release, first patient has been enrolled in the study.